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As little as a decade ago, generation of a single knockout mouse line was an expensive 
and time-consuming undertaking available to relatively few researchers. The International 
Knockout Mouse Consortium, established in 2007, has revolutionized the use of such 
models by creating an open-access repository of embryonic stem (ES) cells that, through 
sequential breeding with first FLP1 recombinase and then Cre recombinase transgenic 
mice, facilitates germline global or conditional deletion of almost every gene in the mouse 
genome. In this Case Study, we describe our experience using the repository to create 
mouse lines for a variety of experimental purposes. Specifically, we discuss the process 
of obtaining germline transmission of two European Conditional Mouse Mutagenesis 
Program (EUCOMM) “knockout-first” gene targeted constructs and the advantages and 
pitfalls of using this system. We then outline our breeding strategy and the outcomes of 
our efforts to generate global and conditional knockouts and reporter mice for the genes 
of interest. Line maintenance, removal of recombinase transgenes, and cryopreservation 
are also considered. Our approach led to the generation of heterozygous knockout 
mice within 6 months of commencing breeding to the founder mice. By describing our 
experiences with the EUCOMM ES cells and subsequent breeding steps, we hope to 
assist other researchers with the application of this valuable approach to generating 
versatile knockout mouse lines.
Keywords: eUCoMM, conditional knockout, Cre recombinase, Flp recombinase, mouse model, inducible 
knockout, C57BL/6
Introduction
The humble laboratory mouse has had a home in scientific research since the 15th century, and 
continues to prove an indispensable resource for investigators wishing to unravel the biology of 
mammalian development, genetics, physiology, and pathology. This is largely due to the mouse’s small 
size and resource demand, short generation time, and suitability for breeding within a laboratory 
environment (1). With the development of “gene targeting” technologies using mouse embryonic 
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stem (ES) cells in the late 20th century, researchers gained the 
ability to selectively mutate the mouse genome at loci of their 
choice (2). However, the promises of this technology are depend-
ent on a high level of expertise in targeting vector design, ES cell 
isolation, and culture and surgical embryo implantation. Moreover, 
this process is time consuming and expensive. Clearly, researchers 
who are eager to commence animal studies would benefit from a 
library of pre-mutated mouse ES cells; a need that was addressed 
last decade with the establishment of the International Knockout 
Mouse Consortium (IKMC).
The IKMC was established in 2007 with the aim of mutating all 
protein-coding regions of the mouse genome using gene targeting 
and gene trapping in C57BL/6 mouse ES cells (3). The IKMC is 
itself a consortium of partner programs: Knockout Mouse Project 
(KOMP) (USA), European Conditional Mouse Mutagenesis 
Program (EUCOMM) (Europe), EUCOMM: Tools for Functional 
Annotation of the Mouse Genome (EUCOMMTOOLS) (Europe), 
North American Conditional Mouse Mutagenesis Project 
(NorCOMM) (Canada), and Texas A&M Institute for Genomic 
Medicine (TIGM) (USA) (4). Prioritization of targets has been 
based upon community demand, expert committees, and the 
perceived importance of individual genes, with little overlap 
between programs (3). In our case, both of our genes of interest 
were targeted and available through EUCOMM, so we will focus 
this review on the gene targeting approach specific to EUCOMM 
ES cells. For more information on the development of the IKMC 
and gene targeting, we refer the reader to Capecchi (2), Skarnes 
et  al. (5), and Bradley et  al. (4). As of 2012, more than 17,400 
ES cell lines had been generated by the IKMC for targeted gene 
deletion (4).
eUCoMM Gene targeting strategy
One of the challenges faced by the IKMC was the design of simple 
and broadly applicable targeting vectors. The main EUCOMM 
strategy has been to develop “knockout-first” conditional allele 
targeting, a powerful approach that allows both reporter-tagging 
and conditional mutation of a given gene-of-interest (GOI). 
Development of the various targeting vectors is described in detail 
in the original paper (5); here, we provide an outline of how this 
approach would be applied to a prototypical GOI containing three 
exons with exon 2 having been identified as “critical” for gene func-
tion. Shown in Figure 1, an IRES:lacZ trapping cassette (internal 
ribosome entry site upstream of lac Z) is placed 5′ of a loxP-flanked, 
promoter-driven, neomycin-resistance selection cassette, which 
lies immediately upstream of exon 2. The neomycin-resistance 
cassette facilitates in vitro selection of targeted ES cells, while the 
lacZ cassette can be used in the generation of reporter-tagged 
animals, i.e., animals expressing lacZ in the tissues that express 
the GOI. A third loxP site is inserted immediately after exon 2 
to facilitate its removal and therefore generation of experimental 
knockout animals in which both alleles of the GOI have been 
inactivated; hence, they are homozygous null for the GOI. To allow 
simultaneous removal of both the lacZ and neomycin-resistance 
cassettes, two FRT (flippase recognition target) sites are inserted 
in the allele; one upstream of the lacZ cassette and one between 
the neomycin-resistance cassette, and the loxP site immediately 
before exon 2. This allele is referred to as “targeted mutation 1a” 
(tm1a), and is designated “knockout-first,” because the insertion 
of the lacZ trapping allele is itself expected to disrupt splicing of 
the GOI, although both the neomycin-resistance and lacZ cassettes 
should be removed before assessment of the knockout phenotype 
(see below).
A key feature of the EUCOMM system is that the vector 
design is versatile and high-throughput. As such, EUCOMM 
employed automated gene annotation and a computer-assisted 
vector design pipeline (5), whereby the 5′-most “critical” exon is 
identified and targeted for deletion – a critical exon is one that 
will lead to a frameshift if deleted, is common to all transcript 
variants and will disrupt >50% of the protein-coding region of 
the GOI (4). Once identified, an algorithm was used to choose 
50-mers suitable for recombineering and placement of loxP sites 
in intronic regions where they are unlikely to disrupt transcription. 
While this approach has enabled the EUCOMM team to target 
thousands of GOIs, this targeting system can only be applied to 
approximately 40% of protein-coding genes (5). Genes with just 
one or two exons, those lacking an exon that is common to all 
isoforms, or where alternative 5′ transcripts exist, must be targeted 
using alternative methods (generated by the other members of 
the IKMC). Although mice bearing the tm1a allele will effectively 
have their GOI deleted, additional breeding steps are needed to 
create appropriate reporter or knockout experimental animals, as 
outlined below and in Figure 1.
Generation of lacZ Reporter Mice
In addition to targeted gene silencing, the elegant EUCOMM 
allele design features the potential to replace GOI translation with 
expression of a β-galactosidase enzyme (from the lacZ cassette), 
providing a means to ask where the GOI is normally expressed. 
β-galactosidase expression can be assessed at the resolution of 
tissues and cell types, using either histochemical staining or immu-
nohistochemistry (6). The advantage of performing immunohis-
tochemistry to detect the β-galactosidase protein, instead of the 
native GOI product, is that researchers can employ well-established 
and sensitive β-galactosidase immunohistochemistry protocols, 
instead of having to design a protocol for their own GOI, which 
in many cases may not have been subjected to detailed evaluation 
and may be heavily dependent on the availability of high quality 
antibodies. This is particularly important for G protein-coupled 
receptors, for example, where the specificity of “specific” antibodies 
is often poor, as shown by similar staining patterns in both wild 
type and knockout mice (7–9).
By crossing tm1a mice with a global “Cre deleter” mouse [a 
transgenic B6.C-Tg(CMV-Cre)1Cgn/J (The Jackson Laboratory, 
USA, Stock number 006054) mouse expressing Cre recombinase 
ubiquitously under the control of a human cytomegalovirus 
(CMV) promoter], recombination at loxP sites results in deletion 
of both the neomycin cassette and exon 2, leading to the generation 
of tm1b, lacZ reporter mice that express β-galactosidase in cells 
where the GOI would ordinarily be expressed (Figure 1). The Cre 
is X-linked in this mouse line due to random integration of the 
transgene into the X chromosome, but expression of Cre recom-
binase precedes X-inactivation, thus gene excision will proceed 
efficiently in both male and female mice (10). Where offspring 
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inherit both a tm1a allele and a Cre allele, loxP sites are cut and 
recombined, removing the neomycin-resistance selection cassette 
and exon 2 of the GOI, while preserving the lacZ cassette.
Generation of “Floxed” Mice
As a first step toward generating the knockout line and to also 
restore GOI expression to that of a pseudo-wild type animal, 
heterozygous tm1a mice are crossed with transgenic C57BL/6J 
mice expressing an enhanced variant of Saccharomyces Cerevisiae 
FLP1 recombinase (FlpE) in all tissues, under the human β-actin 
promoter (transgenic B6.Cg-Tg(ACTFlpE)9205Dym/J, available 
from The Jackson Laboratory, USA, Stock number 005703) (11). 
Where offspring inherit both the tm1a allele and the FlpE allele, the 
FRT-flanked region of tm1a is excised and recombined, removing 
both the lacZ and neomycin-resistance cassettes and restoring 
GOI expression. These mice are referred to as tm1c or “floxed” 
mice and serve as both the founder line for the generation of 
knockout mice and as the control line for experiments. tm1c mice 
are essentially “wild type” as the only difference between their 
allele and that of wild type C57BL/6 mice is the introduction of 
two loxP sites flanking exon 2; however, this should be confirmed 
experimentally in the unlikely event that the loxP sites have 
disrupted gene splicing or an important regulatory or enhancer 
element within the introns.
Generation of Knockout Mice
Finally, breeding of tm1c with either the same Cre deleter mouse 
as for tm1b, or alternatively with a tissue-specific or inducible 
Cre deleter mouse (discussed in the next section), leads to the 
generation of “tm1d” mice, i.e., animals in which exon 2 of the 
GOI has been deleted and the residual gene transcript is likely 
degraded as a result of nonsense-mediated decay (Figure 1). A 
more detailed description of the breeding strategies we employed 
to generate each line is outlined later.
FIGURe 1 | eUCoMM targeting vector construction. Schematic of the EUCOMM vector design illustrating the targeting and recombination process for a 
prototypical gene with three exons (black boxes). See text for description. Figure adapted from Skarnes et al. (5).
Advantages and disadvantages of the 
eUCoMM system
eUCoMM Mice do not Require Backcrossing 
Because they Use C57BL/6 es Cells
Historically, early gene targeting efforts were performed using 
ES cells derived from various 129 substrains, largely because 
they are easier to work with and have resulted in high rates of 
germline transmission. However, few studies are now performed 
using the 129 background because these mice breed poorly, are 
susceptible to testicular teratomas, and are known to display 
other phenotypic abnormalities, e.g., behavioral changes (12). 
Instead, germline transmission is often tested on the preferred 
C57BL/6 mouse background, as these mice are better breeders, 
are the reference strain for the first mouse genome (13), are the 
background for many Cre modifying transgenic mice, and are 
widely used throughout the research community because of 
their marked and well-characterized responses to many disease 
models1 (e.g., diet-induced obesity, diabetes, atherosclerosis). 
Moreover, if germline transmission is established using 129 ES 
cells, the resultant mice must be further crossed to C57BL/6 
mice for 10 generations for the line to be considered congenic 
[note that the genes located very close to the GOI will likely 
still be from the 129 strain and may lead to “passenger gene” 
effects (14)]. A significant advance in the field, brought about in 
large part due to the efforts of the IKMC and EUCOMM, is the 
generation of thousands of knockout-first alleles using C57BL/6 
ES cells (15). By using these cells to generate chimeras, research-
ers can obviate the need for time- and resource-demanding 
backcrossing and be assured that their mice have a pure genetic 
background.
1 www.jaxmice.jax.org
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J vs N: What’s in a Name?
The use of C57BL/6 ES cells is undoubtedly one of the major selling 
points of the EUCOMM system, along with the ability to produce 
conditional-ready knockout-first mice. However, one should be 
aware of subtle differences between sub-strains of C57BL/6 mice. 
In developing the JM8 ES cells used for the EUCOMM pipeline, 
Pettitt et al. preferred the less common C57BL/6N sub-strain to 
the C57BL/6J because the 6N cells demonstrated superior growth 
and morphology when compared to their 6J cousins (15). Yet, the 
genetic background of the FlpE and Cre deleter mice required for 
subsequent EUCOMM breeding steps is usually C57BL/6J [e.g., 
B6.Cg-Tg(ACTFlpE)9205Dym/J, stock number 005703; B6.C-
Tg(CMV-Cre)1Cgn/J, stock number 006054; and B6.FVB(129)-
Tg(Myh6-Cre/Esr1*)1Jmk/J, stock number 005657; available 
from The Jackson Laboratory, USA], meaning that subsequent 
generations of these mice would effectively represent backcrossing 
to a C57BL/6J genetic background. Thus, even after 10 genera-
tions of crossing to C57BL/6J mice, a small confounding section 
of C57BL/6N genetic material would remain around the selected 
allele, estimated at ~20 cM (16). C57BL/6J and C57BL/6N have 
been separated for at least 220 generations (as of 2013) and until 
recently were characterized by relatively few genetic differences, 
the most common being a five exon deletion in the nicotinamide 
nucleotide transhydrogenase (Nnt) gene in C57BL/6J mice, result-
ing in altered insulin secretion and glucose tolerance (17, 18). 
Minor phenotypic differences have also been noted, such as retinal 
degeneration in C57BL/6N mice (19) and behavioral differences 
between the C57BL/6 sub-strains (20). More recently, however, 
next generation sequencing of both sub-strains revealed 34 coding 
single nucleotide polymorphisms (SNPs), 2 coding small indels 
(insertions/deletions), 146 non-coding SNPs, and 54 non-coding 
small indels (21). Furthermore, using the broad and carefully 
standardized EMPRESSslim phenotyping pipeline, Simon et al. 
identified 27 phenotypic features that were significantly different 
between the two sub-strains and that were consistently found to 
differ even when performed at multiple research centers (21). These 
differences were in categories such as ophthalmology, cardiovascu-
lar health, metabolism, behavior, clinical chemistry, hematology, 
and immune function (21). Given the increased recognition of 
such phenotypic differences, careful design of animal breeding 
strategies and interpretation of experimental results are required.
Choice of Cre Recombinase Mouse Gives 
temporal and spatial Flexibility
One of the most powerful aspects of the EUCOMM system is 
the capacity to modify gene deletion in a tissue- or time-specific 
manner by breeding tm1c mice with specialized Cre recombinase 
lines. While a global tm1d mouse can be generated by crossing 
tm1c with the CMV-driven Cre recombinase mice outlined 
above, there are many cases in which global deletion is not ideal. 
This is best illustrated in a recent study by the Sanger Institute 
Mouse Genetics Project that described the careful phenotyping 
of 489 targeted alleles from the EUCOMM system, where 42% 
of genes were found to be essential for viability (29% lethal, 13% 
sub-viable) (22). In such cases, or where a developmental defect 
confounds investigation of an adult condition, an inducible Cre 
recombinase would allow deletion of the GOI after the mouse 
has reached adulthood. For the inducible transgenes, Cre recom-
binase is most commonly fused to a modified estrogen receptor 
that preferentially binds tamoxifen instead of estrogen (23). The 
Cre recombinase is constitutively expressed but remains in the 
cytoplasm, physically separated from the floxed gene of interest. 
Upon binding to tamoxifen, Cre recombinase now translocates 
to the nucleus where it excises floxed genes by recombination at 
loxP recognition sites (23).
Another powerful example of the utility of the EUCOMM 
approach is the ability to decipher the tissue-specific physiology 
that underpins a phenotype seen in a global gene deletion, either 
in an inducible or constitutive manner, by using cell type- or 
tissue-specific promoters to drive Cre expression. For example, 
angiotensin II (AngII) has long been known to contribute to blood 
pressure homeostasis via the ubiquitously expressed angiotensin 
type 1 (AT1) receptor. Elegant studies by Tom Coffman and col-
leagues, in which they cross-transplanted kidneys from wild type 
and AT1 knockout mice, demonstrated that renal AT1 receptors 
are critical for maintaining baseline blood pressure (24) and are 
necessary for AngII-mediated cardiac hypertrophy (25). However, 
the AT1 receptor is expressed in multiple cell types within the 
kidney, so further studies required cell-type specific Cre deletion 
of the AT1 receptor to further understand the mechanism of these 
findings. Subsequent studies with either PEPCK-Cre (phospho-
enolpyruvate carboxykinase-Cre) (26) or inducible KAP2-Cre 
(kidney androgen-regulated protein-Cre) (27) driven excision of 
the AT1 receptor from the renal proximal, but not distal, tubules 
demonstrated that it was this sub-population of cells responsible 
for the observed phenotype. The incredible flexibility afforded 
by the EUCOMM conditional-ready mice is underlined by the 
availability of more than 2000 Cre mouse strains (not all are live 
stock); suitable mice can be searched for using the Cre portal at the 
Mouse Genome Informatics website2 or the International Mouse 
Strain Resource3.
eUCoMM Mice still Require Multiple 
Generations of Breeding to Remove 
Contaminating transgenes and the Neomycin 
selection Cassette
As discussed above, the use of C57BL/6 ES cells obviates the need 
for 10 generations of backcrossing to achieve genetic homogeneity 
if the target genetic background is also C57BL/6. Furthermore, the 
fact that the tm1a mice are considered to be knockout-first means 
that initial phenotyping can be performed immediately and without 
further breeding steps. This is particularly advantageous for larger 
scale phenotyping exercises such as the Sanger Institute Mouse 
Genetics Project (22), which used brother–sister matings of tm1a 
heterozygotes to generate homozygous “nulls” for their phenotyping 
screen (see Figure 2 for pipeline). In general, however, it is desirable 
to remove both the neomycin cassette (by crossing with FlpE mice 
to generate tm1c) and any remaining recombinases (either FlpE or 
Cre) before phenotyping the knockout mice, since both have been 
2 www.informatics.jax.org/recombinase.shtml
3 www.findmice.org/summary?mutations=recombinase(cre/flp)
FIGURe 2 | outline of phenotyping protocol for eUCoMM mice used by 
the sanger Institute Mouse Genetics Project. The Sanger Institute Mouse 
Genetics Project describes a standardized series of tests applied to novel 
EUCOMM lines. Chimeric mice are outcrossed with C57BL/6 to determine 
germline transmission (GLT) and heterozygous tm1a mice intercrossed to 
assess viability at 14 days after birth. If viable, homozygous tm1a mice enter the 
Mouse Genetics Project (MGP) standardized phenotyping pipeline or are tested 
for fertility. In the case of embryonic lethality or poor survival, heterozygous mice 
are used for the MGP pipeline and homozygous embryos examined at E14.5 to 
determine the cause of sub-viability. In parallel to the intercross protocol, a 
subset of heterozygous tm1a mice are crossed to Cre recombinase mice to 
generate lacZ reporters. Figure adapted from White et al. (22).
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linked to phenotypic effects independent of those due to inactiva-
tion of the GOI. For example, Cre recombinase can introduce DNA 
alterations via cryptic loxP sites in the mammalian genome (28), 
with pathogenic consequences reported in the gastrointestinal (29), 
respiratory (30), and cardiovascular systems (31, 32), to name a 
few. Similarly, retention of antibiotic selection cassettes, such as 
those used in the EUCOMM system, can cause direct disruption 
of gene regulatory elements and unexpected disruption of genes 
far downstream from the initial mutation. Strikingly, Pham et al. 
(33) report disruption of genes more than 100 kb downstream of 
the phosphoglycerate kinase (PGK)-Neo cassette site within the 
granzyme B cluster (33). Similarly, insertion of PGK-Neo in the 
human β-globin locus control region was sufficient to induce at 
least a twofold reduction in the expression of all genes in the locus, 
but, importantly, this phenomenon was found to be reversible upon 
subsequent removal of the cassette (34). Thus, despite EUCOMM 
mice being “knockout-first,” we believe it is essential to breed the 
mice for several generations to achieve knockout and floxed mice 
that will be free of interference from exogenous sequences.
Case study: Generation of two different 
Knockout Mouse Lines Using eUCoMM 
es Cells
Like most research groups, we wanted to be able to generate our 
transgenic mouse lines in the quickest and most efficient manner 
possible. In this section, we describe the generation of each of 
the lines outlined above for two GOIs and the breeding strategies 
employed. All animal studies were performed according to the 
Australian Code for the Care and Use of Animals for Scientific 
Purposes, 8th Edition (2013) and were approved by the Garvan 
Institute of Medical Research/St Vincent’s Hospital Animal Ethics 
Committee under project numbers 11/26 and 13/30.
Germline transmission from eUCoMM es Cells
We outsourced the initial generation of tm1a heterozygotes to the 
Monash University Embryonic Stem Cell-to-Mouse (ES2M) facil-
ity, an Australian Government-subsidized fee-for-service initiative 
designed to provide live IKMC mice to academic researchers.4 Due 
to the facility’s size, expertise, and collaborations, the generation 
of transgenic mice via ES2M is both time- and cost-efficient, 
and subject to stringent quality control. The descriptive statistics 
describing critical parameters in this process, from ordering ES 
cell clones to the generation of tm1a heterozygotes for our two 
GOIs, is displayed in Table 1. For a repository-wide description of 
germline transmission rates for KOMP mice, we refer the reader 
to www.komp.org/gltrates.php.
Based upon past experience and anecdotal evidence that 
germline transmission may be more difficult to achieve with 
C57BL/6 ES cells, ES2M staff recommended four ES cell clones 
per GOI be purchased from EUCOMM (35). For GOI-1, we 
found that only one of the four clones passed quality control (two 
clones had an abnormal karyotype and one clone did not actu-
ally contain the tm1a allele). Of the only clone with a suitable 
karyotype for microinjection, three rounds of injections were 
required to achieve germline transmission – of 21 chimeras, 
eight showed sufficient coat-color chimerism to warrant breed-
ing with C57BL/6J mice to test for germline transmission and 
only one of these chimeras produced heterozygote offspring. 
Thus, 5/354 pups carried our transgene of interest (1.4% success).
4 http://www.australianphenomics.org.au/
tABLe 1 | Germline transmission of genes of interest using eUCoMM es cells.
Clone Karyotype Injected # injections # chimeras Chimeras mated
Injection # % # litters # pups # hets # litters for hets
GOI-1#1 15/20 40, Y Yes 3 21 (5F) 1 M 90 5 29 0 –
1 M 75 4 63 0 –
1 M 60 0 0 – –
1 M 55 7 63 0 –
1 M 50 8 74 0 –
3 M 95 0 0 – –
3 M 80 8 68 5 1
3 M 65 8 56 0 –
GOI-1#2 Abnormal karyotype No – – – – – – – –
GOI-1#3 Abnormal karyotype No – – – – – – – –
GOI-1#4 16/20 40, Y No – not targeted – – – – – – – –
GOI-2#1 10/20 40, Y No, low karyotype – – – – – – – –
GOI-2#2 Clone unavailable – – – – – – – – –
GOI-2#3 15/20 40, Y Yes 2 0 – – – – – –
GOI-2#4 13/20 40, Y Yes 4a 4 2 M 65 0 – – –
3 M 70 5 49 21 1
3 M 60 1 12 0 –
4 M 60 2 17 0 –
Hets, heterozygotes.
aNote that only three injections were required for germline transmission. The fourth injection was performed in parallel as a back-up.
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For GOI-2, only three of four clones were available for shipping 
and one clone had ≤50% euploidy and therefore failed the necessary 
criteria for injection (35). GOI-2 clone #3 was first chosen for micro-
injection because of its favorable karyotype but failed to produce live 
births from either injection round. In contrast, GOI-2 clone #4 had 
a lower karyotype but resulted in four chimeras, albeit from four 
rounds of injections. Fortuitously, one of the four chimeras showed 
germline transmission, producing 21 offspring (26.9% success).
On average, the time from ES2M order submission to arrival of 
heterozygous tm1a mice at our animal facility was 28 months. It is 
important for researchers to accommodate at least 4 months from 
the time of order for receipt of the ES cells from EUCOMM, a com-
mon processing time for the international consortia (35). In our 
case, we experienced a longer time to germline transmission than 
most because of the quality of our ES cells – while KOMP-derived 
ES cells are routinely subjected to quality control screening before 
dispatch, this has only recently been implemented by EUCOMM 
(35). As outlined in Table 1, only three of the eight ordered clones 
were of passable quality, the remaining being either morphologi-
cally or karyotypically abnormal or incorrectly targeted. In contrast 
to the >2 years to germline transmission, breeding and expansion 
of the lines was rapid.
Receipt of tm1a Founders and expansion of the 
Breeding Colony
We received 5 GOI-1 (3 male, 2 female) and 12 GOI-2 (5 male, 
7 female) tm1a mice from the Monash University ES2M facility 
and decided to immediately expand our colony in a single breeding 
step, shown in Figure 3, to ensure we had enough tm1a heterozy-
gotes for subsequent line generation. As described in Table 2, we 
set up 10 breeding pairs (BPs) for GOI-1 and six for GOI-2, so 
that within one generation (3 weeks gestation and 8 weeks to reach 
sexual maturity) we had established colonies with the expected 
Mendelian inheritance ratios (indicating that our GOIs did not 
affect heterozygous animal viability). Any subsequent litters were 
used for cryopreservation and reserves (see below). Also discussed 
below, careful monitoring of all litters produced is critical given 
that the tm1a mice are knockout-first and the mice may have 
unexpected phenotypes that adversely affect their welfare.
Generation of lacZ Reporter Mice for 
Characterization of Gene expression Patterns
Generation of tm1b, or lacZ, reporter mice required a two-step 
breeding strategy to achieve recombinase-free lacZ heterozygotes 
within 6 months. Outlined in Figure 4 and Table 2, eight BPs were 
established involving male Cre hemizygotes on a congenic C57BL/6 
background (10) crossed to tm1a females to produce a single litter 
and male pups were culled prior to weaning, thus ensuring that all 
remaining offspring were heterozygous for Cre. After genotyping 
for tm1a to tm1b conversion, positive females were outcrossed to 
wild type C57BL/6J males and then all female offspring culled – we 
adopted this conservative approach of culling all females when only 
half would be Cre positive because it was the only way to ensure Cre 
was removed from our line (in contrast to genotyping, where a nega-
tive result could reflect a genotyping failure, rather than the absence of 
Cre; given the known effects of Cre contamination, this was not a risk 
we were prepared to take). At this stage, Cre negative tm1b mice can be 
used for characterization of GOI expression, or as breeders for colony 
establishment. Traditionally, a single copy of the lacZ transgene is 
sufficient for β-galactosidase staining or immunohistochemistry. It 
should be noted, however, that these mice are effectively heterozygous 
knockouts and should be monitored accordingly.
Floxed Mice Generation and simultaneous 
Removal of Flpe
Floxed, or tm1c, mice were generated by crossing with FlpE 
recombinase transgenic mice on a congenic C57BL/6J background 
(11). For GOI-1, we had yet to establish a homozygous colony of 
tABLe 2 | Breeding statistics for the first generation of each eUCoMM line.












Genotype %  
(expected %)
Genotype by 
sex (% desired 
genotype)
desired other Male Female
GoI-1
tm1a tm1a/wt × wt or wt × tm1a/wt 10 2 139 61.2 5.8 5.0 54.1 tm1a (50) 45.9 wt (50) 58.8 46.5
tm1b tm1a/wt x Cre/Y 8 1–2 88 0a (52.3) 7.3 1.1 36.1 tm1b (25) 63.9 tm1a or 
Cre only (75)
n.a. 36.6
tm1c Flp/wt x tm1a/wt 10 1–2 120 57.9 6.6 16.8 26.5 tm1c (25) 73.5 tm1a or 
Flp only (75)
29.5 23.1
tm1d Cre/Cre x tm1c/wt 7 1–2 80 38.7 7.3 0 34.2 tm1d (50) 65.8 wt (50) 32.2 35.4
GoI-2
tm1a tm1a/wt x wt or wt x tm1a/wt 6 1–4 64 100a (43.7) 6.4 0 72.2 tm1a (50) 27.8 wt (50) 72.2 n.a.
tm1c Flp/Flp x tm1a/wt or tm1a/
wt x Flp/Flp
8 1 54 46.3 7.7 0 53.7 tm1c (50) 46.3 wt (50) 62.5 50
inducible 
tm1d
tm1c/wt; Flp/wt x MCM/MCM 4 1–3 53 37.7 6.6 1.9 25.7 tm1d and 
MCM (25)




aIndicates that only one sex was weaned. % of total males is indicated in parentheses.
FIGURe 3 | Initial colony expansion of founder mice. Both male and 
female tm1a heterozygotes were outcrossed with C57BL/6J partners to 
increase our breeding colony for subsequent line generation. Listed on the left 
is the time taken from establishing a new breeding pair (BP; numbers indicated 
in red) to the time when offspring are sexually mature (7–8 weeks of age). Mice 
genotypes enclosed in gray boxes are those surplus to requirements, while the 
colored box indicates the desired genotype and the expected Mendelian ratio. 
Inset: key used for remaining figures.
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FlpE mice, so heterozygous × heterozygous pairs were established, 
while GOI-2 homozygous × heterozygous breeding was possible 
later (Figure 5). About eight or 10 BPs were established and in 
both cases the expected Mendelian ratio of tm1c conversion was 
observed (Table 2). A subset of offspring carrying the tm1c allele 
was outcrossed to wild type C57BL/6J mice and floxed heterozy-
gotes, negative for FlpE, were then interbred to establish mice for 
a subsequent two-tiered stem and expansion colony management 
strategy, as per Brennan (16).
Rapid Generation of Knockout Mice
To establish a colony of knockout mice (tm1d) free from both 
FlpE and Cre recombinases in the shortest time possible, we took 
seven FlpE positive floxed males and set up BPs with seven Cre/
Cre females. Resultant offspring had a 50% conversion rate to 
tm1d (as per tm1a heterozygotes, we did not observe lethality 
due to gene deletion) and FlpE negative male or female littermates 
were bred for a subsequent generation (Figure 6). Because the 
Cre recombinase is X-linked in this line, all females from this 
generation were heterozygous for Cre and were therefore culled 
prior to weaning to remove the recombinase from the colony. Male 
offspring were genotyped for the presence of either the tm1d allele 
or Cre recombinase; only tm1d+/Cre- mice were retained. While 
the present breeding scheme has ensured that we have generated 
heterozygous knockout mice within 6 months of receiving our 
founder tm1a mice, by using homozygous Cre female breeders and 
then culling all female offspring we have necessitated an additional 
outcrossing step before we can establish tm1d heterozygous × het-
erozygous BPs and therefore test our homozygous knockouts. 
Using a heterozygous Cre female at this mating step and then 
screening for Cre by genotyping would shorten the time taken to 
achieve the desired genotype by a further generation, or 11 weeks.
Generation of Inducible Knockout  
Mice Within a Year
One of the primary motivators for using the EUCOMM model 
was our desire to generate inducible, tissue-specific knockout 
mice so that we could explore the physiological roles of our GOIs 
without potentially confounding developmental influences. One 
such conditional model is the cardiomyocyte-specific deletion 
FIGURe 5 | Floxed mice generation. Female FlpE recombinase 
heterozygotes (or homozygotes in the case of GOI-2, indicated by an asterix) 
were crossed with male tm1a heterozygotes and resultant tm1c-converted 
mice identified by genotyping (*1:2 conversion for GOI-2). The floxed mice 
were subsequently outcrossed and tm1c heterozygotes free of contaminating 
FlpE recombinase were chosen for brother × sister matings and subsequent 
line maintenance.
FIGURe 4 | Generation and maintenance of lacZ reporter mice. Male 
CMV-Cre mice were crossed with female tm1a heterozygotes and all female 
offspring genotyped for conversion to tm1b (all females must be 
heterozygous for Cre). The recombinase was then removed by crossing tm1b 
convertants to C57BL/6J males and all females culled prior to weaning 
because they potentially carry Cre. Recombinase negative males were then 
used for experiments or used in further breeding before 
heterozygous × heterozygous breeding pairs could be established. 
Homozygous lacZ mice can then be used for timed matings and embryo 
harvest. Note that tm1b mice are themselves knockout mice, so should be 
monitored accordingly for adverse phenotypic effects. Mice in gray boxes are 
surplus to requirements.
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of our GOIs by crossing tm1c heterozygotes with homozygous 
B6.FVB(129)-Tg(Myh6-Cre/Esr1*)1Jmk/J (stock number 005657, 
available from The Jackson Laboratory) (36). This mouse line 
expresses a tamoxifen-inducible Cre recombinase (MerCreMer) 
directed by the mouse cardiac-specific α-myosin heavy chain 
(α-MHC) promoter. Excision is initiated by administration of 
tamoxifen, which binds to the modified estrogen receptor (Mer; 
recognizes tamoxifen but not estrogen) to facilitate transloca-
tion of Cre from the cytoplasm to the nucleus, where it is able 
to remove the loxP-flanked exon 2 of the GOI. Only one copy of 
Cre is necessary for efficient transgene excision while mice must 
be homozygous for tm1c, necessitating multiple breeding steps 
(Figure 7).
Additional Considerations
Animal Welfare and Monitoring
In most cases, the phenotype of tm1a and tm1d mice is either 
unknown or presumed, necessitating careful monitoring of 
mice throughout initial breeding steps to screen for any adverse 
phenotypes that might arise. Aside from experimental interest 
and monitoring for embryonic lethality, this is paramount for 
the welfare of the animals as early identification of detrimental 
effects can alleviate distress. A number of parameters should 
be assessed upon receipt of adult tm1a animals (16) and upon 
the birth of the first litter of all other mouse lines that will be 
generated “in-house” from the EUCOMM system. We devised 
a specific monitoring scheme, adapted from Brennan (16) and 
shown in Figure  8, and found that all lines developed in the 
course of this case study were free of adverse effects or overt 
phenotypic differences. It is important to note that at this stage 
of the breeding scheme, we do not know the genotype of the 
FIGURe 7 | Initial breeding scheme for generation of MerCreMer 
inducible knockout mice. At the same time as generating the tm1d 
knockout mice, we also established an inducible cardiomyocyte-specific 
deletion line. Female tm1c mice were bred to homozygous α-MHC 
MerCreMer (MCM) C57BL/6J males; the tm1c allele was selected for by PCR 
and remains unconverted (requires tamoxifen administration for Cre 
induction), while all FlpE positive offspring were culled at this step. 
Brother × sister matings were established as the stem breeding scheme for 
future generations, while expansion breeding pairs comprised tm1c 
heterozygotes that were either wild type or homozygous for MCM – the 
expansion pairs will yield all necessary experimental mice as well as feed back 
to the stem colony. Stem and expansion breeding is discussed in Ref. (16).
FIGURe 6 | Generation of global knockout mice. Female homozygous 
CMV-Cre mice were crossed with tm1c males such that all offspring bearing 
both tm1c and Cre alleles will convert to tm1d. To hasten removal of the FlpE 
recombinase, only FlpE negative offspring were retained and then crossed to 
wild type C57BL/6J partners. Because CMV-Cre is X-linked, all female pups 
were culled, resulting in a 1:4 ratio of desired recombinase-negative tm1d 
males. Subsequent outcrossing to wild type C57BL/6J females generated 
50% tm1d heterozygotes, which were then intercrossed to generate the 
homozygous knockout line.
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offspring until after weaning. For expediency, we chose to moni-
tor litters without this information, instead focusing on gross 
developmental differences within and between litters. Effects of 
viability of a particular genotype were later dismissed when we 
were able to confirm that all lines displayed expected Mendelian 
inheritance ratios (Table 2).
For litter monitoring, neonates were observed every 2 days from 
birth until weaning (3 weeks). Mortality was assessed and found 
to be minimal except for the GOI-1 tm1c line (Table 2), where 
several litters were destroyed (because this line should be as close 
to wild type as possible, and the fact that no other phenotypic 
differences were observed, we attribute this to the young age of 
the mothers). Neonates were normal and equal in size relative 
to one another, of the expected coat color, free of morphological 
abnormalities, and had a healthy body condition. As per expected 
developmental trajectories, pups were ambulant 7–8  days after 
birth (and exhibited wriggling prior to that time) and responded 
to touch. Milk bands were visible on neonates until approximately 
7–8 days after birth. Weaning and mature mice had body weights 
and growth rates similar to that of their parental strain. Animal 
coats were free of hair loss, skin color was as expected, and mice 
exhibited normal posture and gait. Behaviorally, mice were alert 
and responsive. No clinical signs of poor health (discharge, seizures, 
weight loss, lesions) were observed. It is important to note that 
defects may not appear until a given allele is bred to homozygosity, 
so researchers must be vigilant in monitoring all animals, even if 
no adverse effects are observed following heterozygous alterations 
to the genome.
tamoxifen dosing
One of the great innovations in the Cre-loxP field is the development 
of inducible Cre recombinase transgenic mice. However, these lines 
require extra experimental controls as both the inducing ligand and 
the recombinase may have adverse effects independent of the GOI 
under investigation. For example, it has been shown that induction 
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of Cre expression alone is sufficient to generate a cardiac 
phenotype in the popular α-MHC-MerCreMer mouse line (31, 
32); a major confounding effect when these mice are used to 
investigate the heart. Adverse effects were shown to be from 
the recombinase activity itself, induced by excessive tamoxifen 
dosing, and included apoptosis, myocardial fibrosis, and cardio-
vascular dysfunction (31, 32). Reassuringly, the same studies also 
report successful optimization of tamoxifen dosing to achieve 
a compromise between minimal cardiovascular side effects 
and maximum efficiency of recombination and gene silencing. 
Curiously, the ideal treatment regimen varies between strains 
of mice and between GOIs, making it essential for researchers 
who intend to work with tamoxifen to properly optimize their 
treatment strategy for their own lines.
Cryopreservation of New eUCoMM Mice
For most researchers, generation of genetically modified 
mouse lines is a significant and expensive undertaking, so line 
maintenance and preservation are essential. Cryopreservation 
of either embryos or sperm has a number of advantages over 
continuous maintenance of BPS at a research facility. In addi-
tion to allowing unused lines to be maintained without further 
breeding, which saves space and costs associated with housing 
and genotyping, cryopreservation provides insurance against a 
number of different scenarios. Loss of a mouse line can occur 
through infection by pathogenic organisms, which in some cases 
can only be eradicated by culling of the entire stock of affected 
animals and restocking from pre-infected sources. Genetic 
diversification occurs over time, through spontaneously arising 
mutations which can become fixed in the colony, or breeding 
mismanagement may also occur, leading to genetic contamina-
tion; see Brennan (16). The Jackson Laboratory, for example, 
routinely protects its inbred colonies against cumulative genetic 
drift by refreshing their breeding stocks every five generations 
with cryopreserved embryos. Cryopreservation also protects 
against the loss of a line in the most extreme circumstances, as 
occurred, for example, during Hurricane Katrina (37) or after 
an animal rights protest in Italy (38), by allowing maintenance 
of cryopreserved samples off-site (many cryopreservation 
services themselves locate samples at multiple different loca-
tions). We chose to submit our strains to the repository at the 
Australian Phenomics Facility, which is a founding member of 
the Federation of International Mouse Resources, where they 
have been archived by sperm cryopreservation to ensure they are 
widely available to the scientific community. Every line gener-
ated in this case study was submitted for cryopreservation of 
sperm from at least five males (mostly the first heterozygous 
males generated), and one straw of 11 frozen from each male 
was used to check for sperm concentration, morphology, and 
motility after thawing. For added insurance, we requested IVF 
confirmation of sperm viability for both tm1a lines, reasoning 
that these mice were most important because they could be 
reanimated to re-establish all subsequent mouse lines should 
individual sperm cryopreservation fail to result in recovery 
of a line. Of course, these are all decisions that are specific 
to the researchers and must fit with their goals and financial 
requirements.
LITTER ASSESSMENT Monitoring sheet
AEC#: Investigator: Species: Mouse
Dam strain: Dam ID#: Dam genotype: Dam DOB:
Sire strain: Sire ID#: Sire genotype: Sire DOB:
Litter Details
Litter #/Breeding Pair #: Fate of Litter (i.e. experiment/reduced)











MONITORING (results given as # pups/total)


















Pup Number 1 2 3 4 5 6 7 8
Sex
Weight





Euthanasia Criteria as per Clinical Signs Checklist. If necessary, pups will be euthanized by decapitation (if less than 10 
days old) or by CO2 asphyxiation and/or cervical dislocation.
FIGURe 8 | sample sheet for animal welfare monitoring of eUCoMM mice. An example of the kind of litter monitoring sheet that should be used to assess 
the welfare of new lines, accounting for mortality, abnormalities or differences in appearance, behavior, responsiveness, and nutrition. Boxes with a strike-through 
are not applicable to that particular age.
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of Cre expression alone is sufficient to generate a cardiac 
phenotype in the popular α-MHC-MerCreMer mouse line (31, 
32); a major confounding effect when these mice are used to 
investigate the heart. Adverse effects were shown to be from 
the recombinase activity itself, induced by excessive tamoxifen 
dosing, and included apoptosis, myocardial fibrosis, and cardio-
vascular dysfunction (31, 32). Reassuringly, the same studies also 
report successful optimization of tamoxifen dosing to achieve 
a compromise between minimal cardiovascular side effects 
and maximum efficiency of recombination and gene silencing. 
Curiously, the ideal treatment regimen varies between strains 
of mice and between GOIs, making it essential for researchers 
who intend to work with tamoxifen to properly optimize their 
treatment strategy for their own lines.
Cryopreservation of New eUCoMM Mice
For most researchers, generation of genetically modified 
mouse lines is a significant and expensive undertaking, so line 
maintenance and preservation are essential. Cryopreservation 
of either embryos or sperm has a number of advantages over 
continuous maintenance of BPS at a research facility. In addi-
tion to allowing unused lines to be maintained without further 
breeding, which saves space and costs associated with housing 
and genotyping, cryopreservation provides insurance against a 
number of different scenarios. Loss of a mouse line can occur 
through infection by pathogenic organisms, which in some cases 
can only be eradicated by culling of the entire stock of affected 
animals and restocking from pre-infected sources. Genetic 
diversification occurs over time, through spontaneously arising 
mutations which can become fixed in the colony, or breeding 
mismanagement may also occur, leading to genetic contamina-
tion; see Brennan (16). The Jackson Laboratory, for example, 
routinely protects its inbred colonies against cumulative genetic 
drift by refreshing their breeding stocks every five generations 
with cryopreserved embryos. Cryopreservation also protects 
against the loss of a line in the most extreme circumstances, as 
occurred, for example, during Hurricane Katrina (37) or after 
an animal rights protest in Italy (38), by allowing maintenance 
of cryopreserved samples off-site (many cryopreservation 
services themselves locate samples at multiple different loca-
tions). We chose to submit our strains to the repository at the 
Australian Phenomics Facility, which is a founding member of 
the Federation of International Mouse Resources, where they 
have been archived by sperm cryopreservation to ensure they are 
widely available to the scientific community. Every line gener-
ated in this case study was submitted for cryopreservation of 
sperm from at least five males (mostly the first heterozygous 
males generated), and one straw of 11 frozen from each male 
was used to check for sperm concentration, morphology, and 
motility after thawing. For added insurance, we requested IVF 
confirmation of sperm viability for both tm1a lines, reasoning 
that these mice were most important because they could be 
reanimated to re-establish all subsequent mouse lines should 
individual sperm cryopreservation fail to result in recovery 
of a line. Of course, these are all decisions that are specific 
to the researchers and must fit with their goals and financial 
requirements.
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FIGURe 8 | sample sheet for animal welfare monitoring of eUCoMM mice. An example of the kind of litter monitoring sheet that should be used to assess 
the welfare of new lines, accounting for mortality, abnormalities or differences in appearance, behavior, responsiveness, and nutrition. Boxes with a strike-through 
are not applicable to that particular age.
CRIsPR/Cas9: the Way of the Future?
The CRISPR/Cas9 (clustered regularly interspaced short palin-
dromic repeats/CRISPR-associated protein 9) system is a newly 
described technology that promises to be the most efficient 
method yet for targeting ES cells. Briefly, guiding RNA and the 
Cas9 endonuclease are introduced into the targeted cell (either 
by direct injection of the protein or as a DNA construct carrying 
the gene for Cas9), where the guiding RNA comprises a region of 
complementarity to the gene being targeted for disruption and 
a Cas9 binding domain. Cas9 contains two nuclease domains (a 
RuvC-like nuclease domain and a HNH-like nuclease domain), 
one for each strand of a DNA molecule, thereby introducing a 
double-stranded break (39). Permanent disruption of the cleaved 
gene results from the error-prone repair of the double stranded 
breaks, particularly non-homologous end-joining (NHEJ), which 
may result in insertions and deletions that silence the gene by 
introducing a frameshift. These events occur at frequencies 
typically above 1%, and in some cases over 50%, allowing desired 
mutations to be detected with simple screening assays, obviating 
the need for drug-resistance selection markers (40). The efficiency 
and simplicity of CRISPR/Cas9 may one day see this tool surpass 
traditional gene targeting approaches; however, there are a number 
of important caveats to the current application of this technology.
Off-target nuclease-mediated double-stranded breaks are the 
greatest concern as the “protospacer” guiding RNA region can 
tolerate mismatches at up to five positions – a striking number 
given protospacer sequences are typically 20 nucleotides in length 
(40). Using a relatively insensitive assay, it has been reported that 
nuclease-mediated indel mutations will occur in up to 5% of such 
mismatched off-targets (40, 41). This is an important considera-
tion given that any 20 nucleotide sequence will have thousands of 
sequences differing by up to five positions in a genome.
Many approaches to improve CRISPR/Cas9 specificity have 
been explored. Reduced off-target effects are seen with optimi-
zation of the concentrations of both the guiding RNA and the 
Cas9 nuclease, by the use of multiple guiding RNAs targeted at 
the same gene and, most promisingly, the use of paired modified 
Cas9 “nickases” (39). This approach uses two guiding RNAs and 
two types of Cas9, one with a deactivated RuvC-like domain and 
the other with a deactivated HNH-like domain, meaning that each 
enzyme can only break one of the DNA strands on its own. Thus, 
the two guiding RNAs must both find their target to introduce a 
double-stranded break. However, it has been hypothesized that 
passage of a DNA replication fork through a “nick” in just one 
DNA strand can induce a double-stranded break, allowing the 
possibility of mutations arising through NHEJ (40). While screen-
ing for off-target effects is possible and necessary, it is impossible 
to fully assess the extent of potential genetic disruptions without 
completely sequencing the entire genome.
Our laboratory’s decision to create transgenic mouse lines using 
the EUCOMM ES cell library, instead of a CRISPR/Cas9 gene tar-
geting system, was based simply on the availability of our GOIs as 
EUCOMM-targeted ES cells. Had this not been the case, we would 
have had more motive to explore other gene targeting solutions. 
Furthermore, while the Cre-loxP method of gene silencing is not 
without risk of off-target effects, we believe such effects are better 
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characterized and more readily assessed than those associated with 
CRISPR/Cas9 gene targeting technology, which is to be expected 
given the infancy of CRISPR/Cas9 system.
IKMC/eUCoMM or CRIsPR/Cas9: Choosing the 
Right system
CRISPR/Cas9 is clearly going to revolutionize mouse genetics, but 
should we abandon the IKMC/EUCOMM approach already? We 
would argue that both technologies need to be used in parallel, at least 
in the short term. If the goal is to generate knockout mice in either a 
global or time/tissue-specific manner, then the IKMC/EUCOMM 
knockout-first system should be the obvious first choice – the ES 
cells are most likely already archived and will enable rapid genera-
tion of each of the mice needed, as outlined above. To replicate the 
same mice using CRISPR/Cas9 would potentially be more difficult 
(although a simple global knockout is facile), as a large section of 
new genetic material needs to be incorporated in frame into the 
genome (e.g., FRT and loxP sites, lacZ reporter etc.). While CRISPR/
Cas9 can be used to replace genetic information and to introduce 
new DNA, this process relies on homology-directed repair (39), 
which has been met with variable success. At present, CRISPR/Cas9 
remains limited to smaller insertions and the availability of unique 
targeting sequences flanking the gene – it is not always possible 
to target the specific section of DNA desired using the current 
technology. Furthermore, the presence of the Cas9 endonuclease still 
subjects the genome to the risk of unintended mutations (42). New 
innovations in CRISPR/Cas9 technology are appearing regularly, but 
for now we recommend the EUCOMM knockout-first technology 
for generating valuable and flexible knockout mouse models.
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